An international Overall Survival clinical study with the combination of Ceplene and low dose Proleukin.

Trial Profile

An international Overall Survival clinical study with the combination of Ceplene and low dose Proleukin.

Planning
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Aldesleukin (Primary) ; Histamine dihydrochloride (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms REMAIN
  • Most Recent Events

    • 17 Feb 2017 According to an Immune Pharmaceuticals media release, company will announce the launch of this trial at the Acute Leukemia XVI symposium 2017. Patient recruitment is expected to start in later 2017.
    • 22 Nov 2016 According to an Immune Pharmaceuticals media release, following the guidance from the Food and Drug Administration, the Ceplene Scientific Advisory Board (SAB) will review the proposed clinical protocol of this study.
    • 27 Oct 2016 According to an Immune Pharmaceuticals media release, company has received guidance from the United States Food and Drug Administration (FDA) on this study. FDA reviewed the study design and provided feedback relating to specific design elements. Company plans to submit the final protocol for the phase III study in early 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top